Clarke, J. M., Stinchcombe, T., Gu, L., Mamdani, H., Antonia, S. J., Simon, G. R., … Patz, E. (2023). Results from a first-in-human phase 1B study of a complement factor H inhibitor (GT103) in patients with non-small cell lung cancer (NSCLC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Clarke, Jeffrey Melson, Tom Stinchcombe, Lin Gu, Hirva Mamdani, Scott Joseph Antonia, George R. Simon, Guru P. Sonpavde, et al. “Results from a first-in-human phase 1B study of a complement factor H inhibitor (GT103) in patients with non-small cell lung cancer (NSCLC).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Clarke JM, Stinchcombe T, Gu L, Mamdani H, Antonia SJ, Simon GR, et al. Results from a first-in-human phase 1B study of a complement factor H inhibitor (GT103) in patients with non-small cell lung cancer (NSCLC). In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Clarke, Jeffrey Melson, et al. “Results from a first-in-human phase 1B study of a complement factor H inhibitor (GT103) in patients with non-small cell lung cancer (NSCLC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.

Clarke JM, Stinchcombe T, Gu L, Mamdani H, Antonia SJ, Simon GR, Sonpavde GP, Ready NE, Crawford J, Campa M, Gottlin E, Bushey R, Herndon JE, Patz E. Results from a first-in-human phase 1B study of a complement factor H inhibitor (GT103) in patients with non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. 2023.